James Dahlman
James’ first startup company, Guide Therapeutics, was acquired by Beam Therapeutics in 2021. He has since embarked on other entrepreneurial expeditions shaped around his development of RNA therapeutics.
“Biolocity was especially helpful with Guide. I didn’t really know how to talk to investors. The Biolocity team was patient with me and taught me key fundamental business concepts.
“The Georgia Research Alliance has also been really great. For Guide, GRA provided two seed grants and guidance that helped us in the so-called ‘valley of death’ period of early funding. GRA has also provided seed grants for a third venture we’re working on.
“Overall, Emory has established a very supportive ecosystem. When I think about Emory my mind goes to the small molecule scientists who came before me. Their technologies have saved a lot of lives. I’m determined to have a similar impact with RNA therapeutics.”